Seniprutug
Based on 1 Customer Validation
Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9+ T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis.
For research use only. We do not sell to patients.
- Purity: 99.36%
- CAS No.: 2484772-72-5
- Molecular Weight:146.42 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
TRBV9
Seniprutug selectively targets the TRBV9 segment of the T cell receptor β chain, depletes TRBV9+ T cells, while preserving the remaining T cell repertoire[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
28586 [NCBI]
A0A0B4J1U6
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2484772-72-5
-
Appearance Liquid
-
Molecular Weight 146.42 kDa
-
Color Colorless to light yellow
-
Synonyms
BCD-180
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Nasonov EL, et al. The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA. Dokl Biochem Biophys. 2025;522(1):387-403. [Content Brief]
[2]. Um J, et al. Mechanistic Insights from Human Studies in Axial Spondyloarthritis: A T Cell Story. Curr Rheumatol Rep. 2026;28(1):6. Published 2026 Mar 5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Seniprutug Related Classifications
HY-P990762 Related Classifications
Powered by Bioz